Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive ...

Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction ...

Regeneron’s strategy relies on two experimental lab-made antibodies, trevogrumab and garetosmab. Both antibodies are linked to separate proteins that play key roles in limiting skeletal muscle ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the ...

Regeneron has promising muscle preservation in obesity treatment, "Trevogrumab," in phase two. Libtayo is Regeneron's PD-1 inhibitor approved for certain skin cancers and is under investigation ...